In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sonia Lwoff, director, clinical operations, Rho, discusses the potential for artificial intelligence in clinical trial decision-making and enrollment.
ACT: Is there any potential for the use of AI when it comes to decision-making and enrollment?
Lwoff: In the trial development process, AI algorithms can analyze existing data to predict trial outcomes and identify optimal trial designs. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. It's already occurring and when it comes to patient recruitment and enrollment, AI can accelerate recruitment efforts by analyzing electronic health records and other data sources to identify potential participants who may meet the eligibility criteria for one trial. Some site networks are already working with AI to check on their medical records to identify patients. However, we need to be mindful of how this data is being used at hospitals. There are some data privacy considerations. AI can process also and analyze data in real time and detect anomalies and potential issues more quickly than the traditional methods. Last but not least, AI may also be used to analyze previous trials data to start using it for site selection and to predict which sites may perform optimally in a given trial based on the previous experience with those sites.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.